An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus
NCT00135330 on ClinicalTrials.gov · last registry update 2015-04-07
A small phase 3 — 137 participants, against a typical 424. The sponsor logged completion for July 2008. Primary outcome, as filed: Change in ASIiAUC During a Hyperglycemic Clamp Test. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P3
- Drug
- exenatideBydureon, Byetta
- Sponsor
- AstraZeneca
- Sponsor type
- Industry
- Enrollment
- 137
- Started
- 2005-10
- Primary completion
- 2008-07 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in ASIiAUC During a Hyperglycemic Clamp Test.
Conditions studied
Diabetes Mellitus, Type 2
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.